DARE
Dare Bioscience
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DARE Profile
Dare Bioscience, Inc.
A leader in women's health innovation
3655 Nobel Drive, Suite 260, San Diego, CA 92122
--
Dare Bioscience, Inc., was incorporated under the laws of the State of Delaware on November 28, 2005 under the name Tempo Pharmaceuticals, Inc. The company is an oncology-centric clinical-stage company that develops different therapies using its unique dynamic tumor targeting platform. Cerulean Pharma's nano-drug candidates include patented polymers that can be covalently attached to anticancer treatments, or payloads. Cerulean Pharma's leading product candidate, CRLX 101, targets dynamic tumors of nanopharmaceuticals in Phase 2 clinical development and has the ability to address unmet needs that existing cancer treatments have failed to address. The company's nanomedicine is polymer-based nanoparticles that are covalently attached to anti-cancer payloads. The company believes that the particle structures formed by these nano-drugs dynamically target tumors in three steps, a process that distinguishes the company's nano-drugs from other nano-pharmaceutical methods. First, the company's nanomedicine discovered a leak of new blood vessels in the tumor, which became a gateway into the tumor tissue. Second, Cerulean's nanomedicine is actively absorbed by tumor cells, and its nanomedicine is not easily removed from cancer cells due to volume. Third, nanopharmaceuticals provide the continuous release of anti-cancer payloads inside tumor cells.